Urothelial Carcinoma clinical trials in Virginia

Pembrolizumab and sacituzumab govitecan for advanced bladder cancer

This trial tests a new drug combination (pembrolizumab and sacituzumab govitecan) against standard treatment for advanced bladder cancer that has spread or cannot be removed by surgery. It's for people who have already tried an immunotherapy drug like pembrolizumab and another drug called enfortumab vedotin.

Using a blood test to guide immunotherapy after bladder/kidney cancer surgery

This study tests whether a blood test that detects tumor DNA can help guide the use of immunotherapy (nivolumab with or without relatlimab) after surgery for urothelial cancer. The goal is to see if starting immunotherapy based on the blood test results can prevent the cancer from coming back.

Study of UGN-104 for low-grade upper tract urothelial cancer

This trial tests a new treatment called UGN-104 for people with low-grade upper tract urothelial cancer (a type of cancer in the tube that carries urine from the kidney to the bladder). The treatment is given directly into the kidney area to kill cancer cells without surgery.

Adding immunotherapy to radiation for bladder cancer

This trial tests whether adding the immunotherapy drug pembrolizumab to radiation therapy works as well as or better than the usual chemotherapy given with radiation for a type of bladder cancer that has not invaded the muscle. It is for people whose cancer came back or has high-risk features and who would otherwise need to have their bladder removed.

Study of PF-08634404 alone or with enfortumab vedotin for bladder cancer

This trial tests a new drug, PF-08634404, either by itself or together with another drug called enfortumab vedotin, for people with advanced bladder cancer that has spread. The goal is to see if these treatments can shrink tumors or slow the cancer's growth.

Study of LB-LR1109 alone and with atezolizumab for cancer

This trial tests a new drug called LB-LR1109, alone or with atezolizumab, for adults with certain advanced solid tumors, including non-small cell lung cancer. It's for people whose cancer has worsened after standard treatments or who cannot have those treatments.

Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

New OX40 immunotherapy for advanced solid tumors

This trial tests a new immunotherapy drug (INBRX-106) alone or with Keytruda (pembrolizumab) for adults with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug can help the immune system fight cancer.

Study of GB-4362 with EV and pembrolizumab for bladder cancer

This trial tests a new study drug (GB-4362) when added to the usual combination of enfortumab vedotin and pembrolizumab for advanced bladder cancer. It is for people who are about to start this standard treatment and have not had these drugs before.

New drug combinations for advanced solid tumors

This trial tests a new drug called zanzalintinib, which may slow or shrink various types of advanced cancer. It is given together with other cancer treatments, and the study is looking at many different cancers including kidney, prostate, bladder, lung, liver, and more.

Collecting urine to test a new bladder cancer detection method

This study collects urine samples to test UroAmp, a new genetic test that may help detect and monitor bladder cancer. It is for people with bladder cancer or blood in urine who want to help improve cancer detection.

Study for HER2-positive bladder cancer after limited treatment

This Phase 2 trial tests disitamab vedotin alone or with pembrolizumab for urothelial (bladder/urinary tract) cancer that has HER2-positive tumors. It aims to shrink tumors and improve outcomes, including for people who have had limited prior treatment or specific prior drug exposures.

Study of DR-0202 for advanced solid tumors after multiple treatments

This trial tests a new drug, DR-0202, for people with certain advanced cancers that have not responded to at least two prior treatments. It may be an option if standard treatments are no longer working.

ALE.P03 for advanced CLDN1-positive solid tumors

This trial tests a new drug, ALE.P03, for people with advanced or metastatic solid tumors that have a certain protein (CLDN1). The drug is given alone (monotherapy) to see if it can shrink tumors or slow their growth.

Early drug study for advanced cancers that have limited options

This Phase 1 study tests NX-1607 in adults with advanced cancers that are hard to treat with standard care. It focuses on safety and early signs of how well the drug may work in specific cancer types.

Study of IDE892 for advanced solid tumors with MTAP deletion

This study tests a new drug called IDE892, alone or in combination, for people with advanced solid tumors that have a specific genetic change (MTAP deletion). The goal is to see if the drug is safe and whether it can shrink tumors.

AI matches your cancer tests to possible treatment trials

This trial uses an AI system to help match people with certain cancer types and specific tumor test results (like gene or protein markers) to relevant clinical trials. It may help you and your doctor find studies that fit your cancer biology faster.

Immunotherapy and radiation to save the bladder

This trial tests whether combining immunotherapy and low-dose radiation after chemotherapy can help you avoid bladder removal. It's for people whose muscle-invasive bladder cancer has shrunk significantly after initial treatment.

Testing new drugs for high-risk bladder cancer after surgery

This trial tests a new combination of drugs (Dato-DXd plus rilvegostomig) against standard treatments for people with high-risk, muscle-invasive bladder cancer that has been surgically removed. The goal is to see if the new treatment reduces the chance of the cancer coming back.

Study of BL-M07D1 for HER2-positive solid tumors

This trial tests a new drug, BL-M07D1, for people with advanced solid tumors that have a protein called HER2. It is for patients who have already tried at least two other standard treatments.

Study of zanidatamab for HER2-positive solid tumors

This trial tests a drug called zanidatamab in people with advanced solid tumors that have high levels of HER2 protein (called HER2-positive). It aims to see if zanidatamab can shrink or slow the growth of these tumors.

Shorter radiation for bladder cancer with chemo

This trial tests if a shorter course of radiation therapy works as well as the usual longer course for people with bladder cancer who are also receiving standard chemotherapy. The goal is to see if shorter treatment can reduce side effects while still being effective.

Study of EVOLVE104 for advanced bladder and squamous cell cancers

This trial tests an experimental drug called EVOLVE104 for people with advanced bladder cancer or certain types of squamous cell cancers. It aims to see if the drug is safe and if it can help shrink tumors.

Study of STRO-004 for advanced solid tumors

This trial tests a new drug called STRO-004 for people with advanced solid tumors (cancers that have spread or come back). It aims to see if the drug is safe and effective for those who have already tried other treatments.